Atorvastatin - Lipid modification
You are here : Home > Formulary Search > Atorvastatin - Lipid modification
I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
Status 1
Green
Formulations :
- Tablets
Formulary Status :
Associated Icons :
Restrictions / Comments :
Preferred
Documentation
PAD Profile
ChemicalSubstance :
Atorvastatin
Indication :
Lipid modification
Group Name :
Keywords :
Statins, primary hypercholesterolaemia, mixed hyperlipidaemia, familial hypercholesterolaemia, high cholesterol, raised cholesterol, lipid lowering, lipid-lowering
Brand Names Include :
Lipitor
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
3
Other Indications
Below are listed other indications that Atorvastatin is used to treat.
- No records returned.
Other Drugs
Below are listed other drugs that are used to treat Lipid modification.
Committee Recommendations (2)
GENERIC atorvastatin has been considered by the PCN and has been assigned a GREEN traffic light status.
NOTE - the branded product, Lipitor, was considered BLACK at the PCN in May 2017.
NOTE - the branded product, Lipitor, was considered BLACK at the PCN in May 2017.
NICE published CG 181 in July 2014 to update and replace NICE CG 67 and NICE TA 94 (statins for the prevention of cardiovascular events).
This latest guidance replaces all former Surrey guidance for lipid modification - see NICE CG 181 below.
If statin therapy is considered appropriate the guidelines recommend using atorvastin 20mg for primary prevention and atorvastatin 80mg for secondary prevention.